The current study, designed to bridge the results from METEOR, which does not include patients in Japan, assessed the efficacy and safety of cabozantinib in Japanese patients with advanced RCC who had progressed after treatment with a prior VEGFR‐TKI. The gene discussed is KDR; the disease is renal cell carcinoma.